REGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

756.910

Open

743.810

VWAP

750.20

Vol

372.31K

Mkt Cap

77.99B

Low

741.910

Amount

279.31M

EV/EBITDA(TTM)

16.32

Total Shares

105.72M

EV

72.09B

EV/OCF(TTM)

14.48

P/S(TTM)

5.59

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Show More

Events Timeline

(ET)

2026-03-24

05:40:00

Regeneron and Sanofi Get Approval for Dupixent to Treat Moderate-to-Severe Bullous Pemphigoid in Japan

2026-03-09 (ET)

2026-03-09

07:10:00

Regeneron Partners with Hansoh on Obesity Drug Development

2026-02-27 (ET)

2026-02-27

07:10:00

Regeneron and Sanofi's Dupixent Receives Positive EMA Opinion

2026-02-24 (ET)

2026-02-24

09:40:00

Regeneron and Sanofi's Dupixent Approved by FDA for Allergic Fungal Rhinosinusitis

2026-02-19 (ET)

2026-02-19

07:20:00

Regeneron Pharmaceuticals' Garetosmab Accepted for FDA Priority Review

News

NASDAQ.COM

11:04 AMNASDAQ.COM

FDA Accelerates Biosimilar Drug Development and Approves New Treatments

CNBC

AstraZeneca's Lung Disease Drug Meets Trial Targets

Fool

Regeneron Faces Challenges but Shows Potential for Recovery

NASDAQ.COM

03-27NASDAQ.COM

Regeneron's Five-Year Outlook Amid Recovery

NASDAQ.COM

03-24NASDAQ.COM

Dupixent Approved in Japan for Bullous Pemphigoid Treatment

Yahoo Finance

03-24Yahoo Finance

Dupixent Approved in Japan for Bullous Pemphigoid Treatment

22 Analyst Rating

Wall Street analysts forecast REGN stock price to rise

16 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

637.00

Averages

808.50

High

1057

Current: 0.000

Low

637.00

Averages

808.50

High

1057

Wells Fargo

Equal Weight

maintain

$800 -> $825

AI Analysis

2026-03-19

Reason

Wells Fargo

Price Target

$800 -> $825

AI Analysis

2026-03-19

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Regeneron to $825 from $800 and keeps an Equal Weight rating on the shares. The firm thinks new drugs and mechanisms such as CD20, BAFF/APRILs, and next generation complement Inhibitors have potential to expand the generalized Myasthenia Gravis market by more than threefold in the next 10 years, to $15B U.S. and $20B global sales in 2036. Vertex Pharmaceuticals (VRTX), Amgen (AMGN) and Regeneron (REGN) could be the biggest beneficiaries here, and Wells is of the view that there is upside to Street numbers.

Barclays

Overweight

initiated

$923

2026-03-06

Reason

Barclays

Price Target

$923

2026-03-06

initiated

Overweight

Reason

Barclays initiated coverage of Regeneron with an Overweight rating and $923 price target. The shares are "fundamentally mispricing" the company's profits from Dupixent over the near- and medium-term, the analyst tells investors in a research note. Barclays also believes Regeneron's pipeline opportunities are undervalued at current share levels, particularly Lynozyfic. The firm views Dupixent indication expansion as an "underappreciated tailwind" for the company.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN.O) is 17.21, compared to its 5-year average forward P/E of 16.57. For a more detailed relative valuation and DCF analysis to assess Regeneron Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

16.57

Current PE

17.21

Overvalued PE

20.02

Undervalued PE

13.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

11.38

Current EV/EBITDA

10.56

Overvalued EV/EBITDA

14.19

Undervalued EV/EBITDA

8.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

5.80

Current PS

5.37

Overvalued PS

6.93

Undervalued PS

4.67

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

top stocks in health sector

Intellectia · 38 candidates

Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%

Ticker

Name

Market Cap$

Eli Lilly and Co

866.87B

AbbVie Inc

364.65B

AstraZeneca PLC

293.00B

Merck & Co Inc

282.35B

UnitedHealth Group Inc

254.55B

Amgen Inc

188.63B

what stock should I buy today

Intellectia · 52 candidates

Pe Ttm: 12 - 30Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Johnson & Johnson

573.51B

Micron Technology Inc

519.64B

Coca-Cola Co

333.92B

Cisco Systems Inc

313.11B

Merck & Co Inc

286.48B

Linde PLC

228.94B

how to use AI screener

Intellectia · 74 candidates

Market Cap: >= 10.00BRevenue 5yr Cagr: >= 8Pe Ttm: 10 - 25Return On Equity: >= 15.0%Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

JPMorgan Chase & Co

764.45B

Merck & Co Inc

285.83B

Morgan Stanley

245.91B

Royal Bank of Canada

225.22B

Novo Nordisk A/S

169.49B

Charles Schwab Corp

163.06B

what to buy or sell now

Intellectia · 39 candidates

Market Cap: >= 20.00BRevenue 5yr Cagr: >= 8Pe Ttm: 12 - 30Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX, DJI

Ticker

Name

Market Cap$

Exxon Mobil Corp

639.72B

Cummins Inc

74.44B

Halliburton Co

29.18B

Newmont Corporation

124.54B

Ameren Corp

30.41B

Regeneron Pharmaceuticals Inc

78.93B

give me a selection of long term stocks

Intellectia · 27 candidates

Market Cap: >= 50.00BRevenue 5yr Cagr: >= 8Pe Ttm: 12 - 30Return On Equity: >= 13.0%Is Index Component: GSPC

Ticker

Name

Market Cap$

Meta Platforms Inc

1.66T

JPMorgan Chase & Co

775.45B

Micron Technology Inc

471.24B

Merck & Co Inc

287.32B

Morgan Stanley

255.47B

Goldman Sachs Group Inc

244.45B

stock to buy today

Intellectia · 20 candidates

Market Cap: >= 50.00BNet Margin: >= 15.00Pe Ttm: 10 - 25Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

Anglogold Ashanti PLC

63.67B

Agnico Eagle Mines Ltd

123.28B

Canadian National Railway Co

67.41B

Newmont Corporation

138.67B

Novartis

315.82B

CSX Corp

79.31B

best stocks to buy

Intellectia · 28 candidates

Market Cap: >= 30.00BRegion: USRevenue 5yr Cagr: >= 10Pe Ttm: 12 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Meta Platforms Inc

1.62T

Micron Technology Inc

463.33B

American Express Co

231.73B

Novo Nordisk A/S

221.33B

Charles Schwab Corp

166.53B

ICICI Bank Ltd

109.25B

welche us Aktien soll ich heute kaufen?

Intellectia · 53 candidates

Market Cap: >= 0Revenue 5yr Cagr: >= 8Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

JPMorgan Chase & Co

813.77B

Micron Technology Inc

439.39B

Morgan Stanley

287.52B

Goldman Sachs Group Inc

277.15B

Merck & Co Inc

266.87B

American Express Co

247.25B

stock to invest in january 28

Intellectia · 50 candidates

Market Cap: >= 20.00BNet Margin: >= 10.00Revenue 5yr Cagr: >= 8Pe Ttm: 10 - 30Moving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

Taiwan Semiconductor Manufacturing Co Ltd

1.74T

Meta Platforms Inc

1.68T

Micron Technology Inc

439.39B

Novo Nordisk A/S

279.76B

Charles Schwab Corp

183.27B

Nextera Energy Inc

181.23B

i want you to screen usar stock

Intellectia · 17 candidates

Net Margin: >= 15.00Revenue 5yr Cagr: >= 10Pe Ttm: 10 - 25List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Morgan Stanley

287.52B

Goldman Sachs Group Inc

278.76B

Merck & Co Inc

267.41B

Charles Schwab Corp

183.31B

Newmont Corporation

140.53B

Chubb Ltd

118.42B

Whales Holding REGN

Polar Capital Holdings Plc

Freemont Capital Pte. Ltd.

Pacer Advisors, Inc.

ARS Investment Partners, LLC

Two Sigma Investments, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc (REGN) stock price today?

The current price of REGN is 751.79 USD — it has increased 1.91

What is Regeneron Pharmaceuticals Inc (REGN)'s business?

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

What is the price predicton of REGN Stock?

Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regeneron Pharmaceuticals Inc (REGN)'s revenue for the last quarter?

Regeneron Pharmaceuticals Inc revenue for the last quarter amounts to 3.88B USD, increased 2.51

What is Regeneron Pharmaceuticals Inc (REGN)'s earnings per share (EPS) for the last quarter?

Regeneron Pharmaceuticals Inc. EPS for the last quarter amounts to 7.84 USD, decreased -2.97

How many employees does Regeneron Pharmaceuticals Inc (REGN). have?

Regeneron Pharmaceuticals Inc (REGN) has 15410 emplpoyees as of March 30 2026.

What is Regeneron Pharmaceuticals Inc (REGN) market cap?

Today REGN has the market capitalization of 77.99B USD.